Oral Obesity Therapies Market Size Growth: From $4.32 Billion In 2026 To $6.32 Billion By 2030
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Oral Obesity Therapies Market Size, Value And Growth Trajectory Through 2030
The market size for oral obesity therapies has experienced robust expansion over recent years. Projections indicate it will increase from $3.94 billion in 2025 to $4.32 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.7%. This historical growth can be attributed to several factors, including the escalating global prevalence of obesity, a rising awareness of metabolic health risks, the expansion of prescription-based weight management drugs, a surge in clinical research on appetite regulation mechanisms, and an increasing healthcare focus on non-invasive obesity treatments.
The oral obesity therapies market size is projected to experience substantial growth in the upcoming years. It is anticipated to grow to $6. 32 billion by 2030 at a compound annual growth rate (CAGR) of 9. 9%. This expansion during the forecast period is driven by the increasing adoption of oral GLP-1 therapies, a rising demand for personalized metabolic treatments, the growth in telemedicine-based obesity care, the expansion of next-generation oral incretin drugs, and increased investment in obesity drug pipelines by pharmaceutical companies. Notable trends for the forecast period include the expanding acceptance of oral GLP-1 based therapies for appetite regulation and weight management, a surge in the utilization of combination oral obesity drugs targeting multiple metabolic pathways, an escalating need for personalized obesity treatment based on genetic and metabolic profiling, the broadening of telehealth-enabled prescription access for oral weight loss therapies, and the ongoing development of gut hormone modulating oral drugs for improved metabolic control.
Get A Free Sample Report With In-Depth Market Insights:
Oral Obesity Therapies Market Growth Factors Behind Sustained Expansion
The increasing incidence of obesity is projected to drive the expansion of the oral obesity therapies market moving ahead. Obesity is defined as a medical condition marked by an excessive buildup of body fat, which raises the risk of health issues like heart disease, diabetes, and high blood pressure. This condition is primarily on the rise because of greater consumption of calorie-rich processed foods, leading to surplus energy intake and progressive weight gain when not compensated by physical activity. Oral treatments for obesity manage the condition by regulating hunger-related hormones and decreasing calorie absorption, resulting in sustained weight management and enhanced health outcomes. For instance, data from May 2025, released by the Office for Health Improvement and Disparities, a UK-based government body, showed that in 2023–2024, the prevalence of overweight (including obesity) among adults was greater in men (69.7%) compared to women (59.2%). Conversely, obesity by itself was marginally more prevalent in women (26.9%) than in men (26.2%). Consequently, the escalating occurrence of obesity is fueling the growth of the oral obesity therapies market.
Oral Obesity Therapies Market Segment Outlook: Which Categories Are Growing Fastest?
The oral obesity therapies market covered in this report is segmented –
1) By Drug Class: Lipase Inhibitors, Sympathomimetic Appetite Suppressants, Combination Therapies, Oral GLP-1 Agonists, Other Oral Mechanisms
2) By Patient Indication: BMI =30 Primary Obesity, Overweight + Metabolic Comorbidities, Short-term Weight Reduction, Weight Maintenance, Adolescent Populations
3) By Sales Channel: Retail Pharmacies, Mail-order Pharmacies, Telehealth Platforms, Hospital Outpatient Pharmacies, Specialty Pharmacies
4) By Application: Obesity Management, Weight Loss Maintenance, Cardiometabolic Risk Reduction, Pre-Surgical Weight Control
5) By End User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Lipase Inhibitors: Prescription Lipase Inhibitors, Over The Counter Lipase Inhibitors, High Dose Lipase Inhibitors, Low Dose Lipase Inhibitors, Generic Lipase Inhibitors, Branded Lipase Inhibitors
2) By Sympathomimetic Appetite Suppressants: Short Acting Appetite Suppressants, Long Acting Appetite Suppressants, Central Nervous System Stimulants, Adrenergic Appetite Suppressants, Prescription Appetite Suppressants, Extended Release Appetite Suppressants
3) By Combination Therapies: Appetite Suppressant And Antidepressant Combinations, Appetite Suppressant And Anticonvulsant Combinations, Multi Mechanism Combination Therapies, Fixed Dose Combination Therapies, Dual Mechanism Combination Therapies, Triple Mechanism Combination Therapies
4) By Oral Glucagon Like Peptide One Agonists: Daily Oral Glucagon Like Peptide One Agonists, Weekly Oral Glucagon Like Peptide One Agonists, High Potency Glucagon Like Peptide One Agonists, Sustained Release Glucagon Like Peptide One Agonists, Next Generation Incretin Agonists
5) By Other Oral Mechanisms: Serotonin Receptor Modulators, Metabolic Enhancers, Thermogenic Agents, Gut Hormone Modulators, Energy Expenditure Regulators, Dual Incretin Agonists
Oral Obesity Therapies Market Industry Trends Fueling Future Revenue Growth
Leading companies active in the oral obesity therapies market are prioritizing the development of innovative solutions, such as incretin-based therapy, to enhance the effectiveness of weight loss, improve metabolic outcomes, and provide patients with convenient non-injectable treatment options. Incretin-based therapy refers to a category of treatments that either mimic or intensify the action of incretin hormones (like GLP-1) to regulate blood sugar levels, reduce appetite, and promote weight loss. As an illustration, in January 2026, Denmark A/S, a healthcare company from Denmark, launched an LP-1 pill for obesity, known as the Wegovy pill (oral semaglutide), for the chronic management of weight in adults suffering from obesity or who are overweight with related conditions, in addition to diet and exercise. It is also authorized to lower cardiovascular risks such as heart attacks and strokes in individuals with pre-existing heart disease.
Oral Obesity Therapies Market Key Participants And Competitive Landscape
Major companies operating in the oral obesity therapies market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Sun Pharmaceutical Industries Ltd., Jiangsu Hengrui Medicine Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Hanmi Pharmaceutical Co. Ltd., Innovent Biologics Inc., Viking Therapeutics Inc., Rhythm Pharmaceuticals Inc., Septerna Therapeutics, Eccogene Inc., Currax Pharmaceuticals LLC, Ascletis Pharma Inc., Structure Therapeutics
View The Full Oral Obesity Therapies Market Report:
Oral Obesity Therapies Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America was the largest region in the oral obesity therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral obesity therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
